Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Study of Telitacicept in Patients With Generalized Myasthenia Gravis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Telitacicept (Primary)
Indications Myasthenia gravis
Focus Registrational; Therapeutic Use
Sponsors RemeGen

Most Recent Events

29 Oct 2025 According to a Remegen media release, Following the 24-week double-blind period, all patients entered the OLE, with those previously on placebo crossing over to telitacicept 240mg.
29 Oct 2025 According to a Remegen media release, the results will be presented in a late-breaking session on October 29 at 10:50am PT at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting.
29 Oct 2025 Results presented in the Vor Biopharma Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com